Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.
Sponsor: Dompé Farmaceutici S.p.A
Terminated
Lack of efficacy observed at 1/3 of the enrollment at investigated dosage. No results available.
Other terminated trials from Dompé Farmaceutici S.p.A
- Recent Onset type1 Diabetes · Phase PHASE2 · Oct 2025
- Dry Eye · Jan 2025
- Infectious Pneumonia · Phase PHASE3 · Sep 2024
- New-onset Type 1 Diabetes · Phase PHASE2 · Oct 2023
- Type 1 Diabetes · Phase PHASE2 · Sep 2023
More terminations from Dompé Farmaceutici S.p.A
Other Bullous Pemphigoid trials with similar outcome
This PHASE2 trial investigates Bullous Pemphigoid and is currently terminated or withdrawn. Dompé Farmaceutici S.p.A leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jan 2024 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Feb 2022 — Sep 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Feb 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dompé Farmaceutici S.p.A
For direct contact, visit the study record on ClinicalTrials.gov .